5-Amino-1-methylquinolinium — abbreviated as 5-Amino-1MQ — is a cell-permeable small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in cellular energy metabolism and NAD+ regulation. Unlike more widely known NAD+ precursors such as NMN or NR, 5-Amino-1MQ works upstream by blocking the enzyme that depletes NAD+ — a mechanistically distinct approach that has attracted growing interest in metabolic and longevity research circles.
What Is 5-Amino-1MQ?
NNMT is an enzyme found primarily in adipose tissue and the liver. Its job is to methylate nicotinamide (a form of vitamin B3), converting it to 1-methylnicotinamide — a reaction that consumes SAM (S-adenosylmethionine), a universal methyl donor. When NNMT is overactive, the result is a double drain: NAD+ precursors are consumed and the SAM pool is depleted, both of which negatively affect cellular energy homeostasis and epigenetic regulation.
5-Amino-1MQ acts as a selective NNMT inhibitor. By blocking this enzyme, it allows intracellular NAD+ levels to rise, preserves SAM availability, and activates downstream longevity and metabolic pathways — particularly SIRT1 and AMPK, both of which are targets of significant anti-aging research. The compound was developed as part of a broader effort to identify small molecules capable of modulating the epigenetic and metabolic consequences of NNMT overexpression in obesity and metabolic disease.
Research Overview
The foundational preclinical research on 5-Amino-1MQ emerged from work on NNMT’s role in adipogenesis and obesity. A pivotal 2021 study by Kannt et al. published in Scientific Reports examined NNMT inhibition as a metabolic strategy, demonstrating that NNMT inhibitors could reduce fat cell differentiation and improve metabolic markers in animal models. Full reference: PubMed PMID 33097782.
Additional research has examined the relationship between NNMT activity and adipocyte biology. Kraus et al. published landmark work demonstrating that NNMT overexpression in white adipose tissue is associated with obesity and that inhibiting the enzyme reduces fat mass in diet-induced obese mice without caloric restriction — a finding with significant implications for metabolic research. Related reading: PubMed PMID 24814516.
The NAD+/SIRT1/AMPK axis activated by NNMT inhibition has extensive scientific literature behind it. SIRT1, a NAD+-dependent deacetylase, regulates glucose and fat metabolism, inflammation, and cellular stress responses. AMPK activation mimics the beneficial effects of caloric restriction and exercise at the molecular level. Community discussion of 5-Amino-1MQ research can be found at: Reddit: 5-Amino-1MQ discussion.
Potential Benefits Studied
- NAD+ elevation: By blocking NNMT-mediated nicotinamide depletion, intracellular NAD+ levels rise — supporting mitochondrial function, DNA repair, and sirtuin activity.
- Anti-obesity and fat reduction: Preclinical studies documented reduced adipogenesis and meaningful fat mass reductions in obese animal models treated with NNMT inhibitors.
- SIRT1 pathway activation: Higher NAD+ availability drives SIRT1 activity, which regulates metabolic gene expression, reduces inflammation, and is associated with longevity pathways.
- AMPK stimulation: NNMT inhibition has been linked to AMPK activation — the same energy-sensing pathway targeted by metformin and caloric restriction.
- Improved insulin sensitivity: Animal models show improved glucose homeostasis and insulin response with NNMT inhibition, relevant to metabolic syndrome research.
- Epigenetic regulation: Preservation of the SAM methyl pool supports broader epigenetic regulation, a mechanism increasingly linked to healthy aging.
Dosage & Administration
5-Amino-1MQ is formulated for oral administration. Research community protocols most commonly reference doses of 50 mg once or twice daily based on allometric scaling from animal studies and self-reported research data. The 50 mg capsule format available for research use provides a standard single-dose unit. The compound demonstrates good oral bioavailability and is typically taken with or without food. Cycle lengths in documented research protocols range from 8 to 12 weeks, with periodic off-cycles recommended for comprehensive biomarker evaluation.
As an NNMT inhibitor with no interaction with hormonal axes, no post-cycle therapy is required. Monitoring NAD+ blood levels, fasting glucose, and lipid panels before and after a research cycle provides meaningful data points for assessing the compound’s metabolic impact in a given subject.
Where to Find It
5-Amino-1MQ 50mg (50 count) formulated for research purposes is available at combatresearch.is. Each unit is 50 mg, providing a full 50-count supply for extended research protocols.
Conclusion
5-Amino-1MQ represents a genuinely novel angle in NAD+ and metabolic research — one that targets the depletion mechanism rather than simply supplementing precursors. The NNMT pathway sits at the intersection of obesity, aging, and cellular energy metabolism, making this compound particularly relevant for researchers interested in metabolic syndrome, longevity biology, and the epigenetic consequences of fat accumulation. As the mechanistic picture continues to develop, 5-Amino-1MQ stands out as one of the more intellectually compelling molecules in current preclinical investigation.
Disclaimer: This article is for educational and research purposes only. 5-Amino-1MQ is not approved for human use by the FDA or any other regulatory authority. This content does not constitute medical advice. Researchers must comply with all applicable laws and institutional guidelines regarding the use of research compounds.
